MX2015000023A - Profármacos novedosos de rebamipida, metodo preparación y su uso. - Google Patents

Profármacos novedosos de rebamipida, metodo preparación y su uso.

Info

Publication number
MX2015000023A
MX2015000023A MX2015000023A MX2015000023A MX2015000023A MX 2015000023 A MX2015000023 A MX 2015000023A MX 2015000023 A MX2015000023 A MX 2015000023A MX 2015000023 A MX2015000023 A MX 2015000023A MX 2015000023 A MX2015000023 A MX 2015000023A
Authority
MX
Mexico
Prior art keywords
producing same
rebamipide
novel
usage
prodrug
Prior art date
Application number
MX2015000023A
Other languages
English (en)
Inventor
Jae Woong Lee
Eui-Hwan Cho
Sung Ju Choi
Sung Woo Lee
Hee Jong Shin
Ho Seok Kwon
Jeong Ho Joo
Hyun Tae Kim
Woo-Heon Song
Jong Bae Yoon
Ki Seok Park
Ho Joon Park
Ho Tae Nam
Original Assignee
Samjin Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49783488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015000023(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Samjin Pharm Co Ltd filed Critical Samjin Pharm Co Ltd
Publication of MX2015000023A publication Critical patent/MX2015000023A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)

Abstract

Se describe un profármaco novedoso de rebamipida, un método para la preparación del mismo y su uso; además una composición farmacéutica que comprende el profármaco novedoso rebamipida como un ingrediente activo se proporciona; el profármaco rebamipida tiene una tasa de absorción 25 veces mayor en comparación con la propia rebamipida y puede ser aplicado para la profilaxis o el tratamiento de la ulcera gástrica aguda, gastritis crónica, xeroftalmia, cáncer, osteoartritis, artritis reumatoide u obesidad.
MX2015000023A 2012-06-26 2013-06-26 Profármacos novedosos de rebamipida, metodo preparación y su uso. MX2015000023A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120068394 2012-06-26
PCT/KR2013/005622 WO2014003424A1 (ko) 2012-06-26 2013-06-26 신규 레바미피드 전구체 및 그 제조방법과 용도

Publications (1)

Publication Number Publication Date
MX2015000023A true MX2015000023A (es) 2015-10-05

Family

ID=49783488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000023A MX2015000023A (es) 2012-06-26 2013-06-26 Profármacos novedosos de rebamipida, metodo preparación y su uso.

Country Status (27)

Country Link
US (1) US11420963B2 (es)
EP (1) EP2865669B1 (es)
JP (1) JP6032451B2 (es)
KR (1) KR101452277B1 (es)
CN (1) CN104662004B (es)
AP (1) AP2015008233A0 (es)
AR (1) AR097226A1 (es)
AU (1) AU2013281442B2 (es)
BR (1) BR112014032627A8 (es)
CA (1) CA2877853C (es)
CL (1) CL2014003496A1 (es)
CO (1) CO7240352A2 (es)
ES (1) ES2875863T3 (es)
IL (1) IL236479A0 (es)
MA (1) MA37676B1 (es)
MX (1) MX2015000023A (es)
NZ (1) NZ704023A (es)
PE (2) PE20160285A1 (es)
PH (1) PH12015500172B1 (es)
RU (1) RU2612509C2 (es)
SA (1) SA113340675B1 (es)
SG (1) SG11201408711PA (es)
TW (1) TWI483727B (es)
UA (1) UA113990C2 (es)
UY (1) UY34882A (es)
WO (1) WO2014003424A1 (es)
ZA (1) ZA201500450B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101692578B1 (ko) * 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
WO2016108319A1 (ko) * 2015-01-02 2016-07-07 삼진제약 주식회사 신규 레바미피드 전구체의 염 및 이의 용도
KR20170094584A (ko) * 2016-02-11 2017-08-21 삼진제약주식회사 레바미피드 전구체를 포함하는 면역질환 및 대사성질환의 예방 또는 치료를 위한 경구투여용 약제학적 조성물
KR102190019B1 (ko) * 2018-10-23 2020-12-15 삼진제약주식회사 쇼그렌 증후군 예방 또는 치료용 조성물
CN111595985B (zh) * 2020-07-09 2022-03-29 苏州正济药业有限公司 一种用hplc测定瑞巴派特有关物质的分析方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578381A (en) * 1982-07-05 1986-03-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JPS6019767A (ja) 1983-07-11 1985-01-31 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体を有効成分とする抗潰瘍剤
JP3621463B2 (ja) 1995-04-26 2005-02-16 大塚製薬株式会社 カルボスチリル誘導体ビスマス塩
KR100669823B1 (ko) 2001-02-20 2007-01-17 경동제약 주식회사 2-(4-클로로벤조일아미노)-3-[2(1ｈ)-퀴놀리논-4-일]프로피온산의 제조방법 및 그 중간체
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
KR20040104020A (ko) 2003-06-02 2004-12-10 진양제약주식회사 신규 레바미피드 리지네이트와 레바미피드 아르기니네이트및 이 신규 레바미피드 리지네이트와 레바미피드아르기니네이트를 유효성분으로 함유하는 약학적 제제
TWI363626B (en) * 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
CN100537541C (zh) * 2004-12-01 2009-09-09 大塚制药株式会社 制备瑞巴派特的改进的方法
JP2008105970A (ja) * 2006-10-24 2008-05-08 Ohara Yakuhin Kogyo Kk ジヒドロキノリン誘導体の製造方法及びその中間体
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
KR101032600B1 (ko) 2008-08-11 2011-05-06 동우신테크 주식회사 고순도 레바미피드의 제조방법
KR101182114B1 (ko) * 2010-03-05 2012-09-12 한림제약(주) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
CN102174015B (zh) 2011-03-07 2013-10-16 江西同和药业有限责任公司 瑞巴派特的精制方法

Also Published As

Publication number Publication date
ZA201500450B (en) 2016-05-25
TW201402118A (zh) 2014-01-16
UY34882A (es) 2014-01-31
MA37676A1 (fr) 2016-10-31
KR101452277B1 (ko) 2014-10-24
SG11201408711PA (en) 2015-01-29
MA37676B1 (fr) 2017-07-31
ES2875863T3 (es) 2021-11-11
PH12015500172A1 (en) 2015-03-16
CA2877853C (en) 2018-01-02
AP2015008233A0 (en) 2015-01-31
US20150141409A1 (en) 2015-05-21
PE20150904A1 (es) 2015-06-13
EP2865669A4 (en) 2015-12-02
PE20160285A1 (es) 2016-04-27
CN104662004A (zh) 2015-05-27
JP2015522585A (ja) 2015-08-06
KR20140001767A (ko) 2014-01-07
PH12015500172B1 (en) 2015-03-16
RU2015102043A (ru) 2016-08-10
US11420963B2 (en) 2022-08-23
AR097226A1 (es) 2016-03-02
BR112014032627A2 (pt) 2017-06-27
WO2014003424A1 (ko) 2014-01-03
RU2612509C2 (ru) 2017-03-09
CA2877853A1 (en) 2014-01-03
AU2013281442B2 (en) 2016-09-15
EP2865669B1 (en) 2021-04-28
TWI483727B (zh) 2015-05-11
CO7240352A2 (es) 2015-04-17
AU2013281442A1 (en) 2015-02-12
NZ704023A (en) 2016-03-31
EP2865669A1 (en) 2015-04-29
SA113340675B1 (ar) 2015-08-16
UA113990C2 (xx) 2017-04-10
CL2014003496A1 (es) 2015-08-07
IL236479A0 (en) 2015-02-26
BR112014032627A8 (pt) 2021-08-31
CN104662004B (zh) 2017-04-19
JP6032451B2 (ja) 2016-11-30

Similar Documents

Publication Publication Date Title
MX2018007022A (es) Metodos para tratar la enfermedad de huntington.
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
IN2015DN01156A (es)
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
MY161088A (en) Agonists of gpr40
MX2015009592A (es) Quinolina y quinazolina amidas como moduladores de canales de sodio.
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
PH12015500172A1 (en) Novel rebamipide prodrugs, preparation method and use thereof
MY159208A (en) A novel formulation of indomethacin
MX2018003975A (es) Combinacion de glicosaminoglicanos y un agente antacido y sus composiciones.
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
TN2014000421A1 (en) Methods of producing anamorelin hydrochloride having controlled chloride content
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
WO2013038200A3 (en) Neurodevelopmental disorders
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2015065628A3 (en) Laquinimod combination therapy for treatment of multiple sclerosis
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
WO2014082738A8 (en) Heteroquinoline-3-carboxamides as kcnq2/3 modulators